Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

An Open-Label, Pilot Study of Bevacizumab in Subjects With Choroidal Neovascularization Secondary to Diseases Other Than Age-Related Macular Degeneration

Authors not listed

Johns Hopkins University · 2005

Abstract

The purpose of this study is to see if the drug bevacizumab is safe and effective to use for people with choroidal neovascularization (CNV). CNV is an eye condition where abnormal blood vessels grow in the part of the eye responsible for central (straight ahead) vision. The drug is produced using recombinant DNA technology and has been approved by the FDA for use in colon cancer. Although not yet approved for people with CNV, the FDA has given permission to use this drug in this study.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-15 MST

Cite this

APA
Anonymous. (2005). An Open-Label, Pilot Study of Bevacizumab in Subjects With Choroidal Neovascularization Secondary to Diseases Other Than Age-Related Macular Degeneration. <em>Johns Hopkins University</em>. https://clinicaltrials.gov/study/NCT00407719
Vancouver
Anonymous. An Open-Label, Pilot Study of Bevacizumab in Subjects With Choroidal Neovascularization Secondary to Diseases Other Than Age-Related Macular Degeneration. Johns Hopkins University. 2005.
BibTeX
@misc{anon2005AnOpen, title = {An Open-Label, Pilot Study of Bevacizumab in Subjects With Choroidal Neovascularization Secondary to Diseases Other Than Age-Related Macular Degeneration}, author = {Anonymous}, journal = {Johns Hopkins University}, year = {2005}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings